No Data
No Data
What's Driving the Market Sentiment Around PepGen?
PepGen Reports Positive Initial Data From Phase I DM1 Therapy Trial
H.C. Wainwright Maintains PepGen(PEPG.US) With Buy Rating, Maintains Target Price $16
Sell Rating on PepGen Inc. Amid Clinical and Regulatory Challenges
PepGen GAAP EPS of -$0.68 Beats by $0.04
Sector Update: Health Care Stocks Advance Late Afternoon